Related Experiment Video
Updated: Jul 3, 2025

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
Published on: March 6, 2018
Unveiling hormone-stimulated gene mechanisms in prostate cancer: A prognostic model, immune infiltration analysis,
Zhongru Fan1, Qianqian Yu2, Junpeng Deng1
1Department of Urology, The Affiliated Suzhou Hospital of Nanjing Medical University, Suzhou Municipal Hospital, Gusu School, Nanjing Medical University, Suzhou, China.
Abstract:
Hormones promote the progression of prostate cancer (PRCA) through the activation of a complex regulatory network. Inhibition of hormones or modulation of specific network nodes alone is insufficient to suppress the entire oncogenic network. Therefore, it is imperative to elucidate the mechanisms underlying the occurrence and development of PRCA in order to identify reliable diagnostic markers and therapeutic targets. To this end, we used publicly available data to analyze the potential mechanisms of hormone-stimulated genes in PRCA, construct a prognostic model, and assess immune infiltration and drug sensitivity. The single-cell RNA-sequencing data of PRCA were subjected to dimensionality reduction clustering and annotation, and the cells were categorized into two groups based on hormone stimulus-related scores. The differentially expressed genes between the two groups were screened and incorporated into the least absolute shrinkage and selection operator machine learning algorithm, and a prognostic model comprising six genes (ZNF862, YIF1A, USP22, TAF7, SRSF3, and SPARC) was constructed. The robustness of the model was validation through multiple methods. Immune infiltration scores in the two risk groups were calculated using three different algorithms. In addition, the relationship between the model genes and immune cell infiltration, and that between risk score and immune cell infiltration were analyzed. Drug sensitivity analysis was performed for the model genes and risk score using public databases to identify potential candidate drugs. Our findings provide novel insights into the mechanisms of hormone-stimulated genes in PRCA progression, prognosis, and drug screening.
Insights
This study identifies six key genes (ZNF862, YIF1A, USP22, TAF7, SRSF3, SPARC) that predict prostate cancer (PRCA) progression. The findings offer new insights into hormone-driven PRCA and potential drug targets.
Area of Science:
- Oncology
- Genomics
- Bioinformatics
Background:
- Hormones drive prostate cancer (PRCA) progression via complex networks.
- Targeting hormones or single network nodes is insufficient for effective PRCA treatment.
Purpose of the Study:
- Elucidate mechanisms of hormone-stimulated genes in PRCA.
- Identify diagnostic markers and therapeutic targets for PRCA.
- Develop a prognostic model for PRCA.
Main Methods:
- Analyzed single-cell RNA sequencing data from PRCA patients.
- Utilized machine learning (LASSO) to construct a prognostic model with six genes.
- Assessed immune infiltration and drug sensitivity.
Main Results:
- Developed and validated a robust six-gene prognostic model (ZNF862, YIF1A, USP22, TAF7, SRSF3, SPARC).
- Analyzed immune cell infiltration patterns associated with risk scores.
- Identified potential drug candidates based on model genes and risk score.
Conclusions:
- The six-gene model provides insights into PRCA mechanisms and prognosis.
- Findings support the role of hormone-stimulated genes in PRCA progression.
- The study highlights potential therapeutic strategies and drug screening opportunities for PRCA.

